Document is current
Any future updates will be listed below
-
Authors
Natori, Keiko
Igeta, Masataka
Morimoto, Takashi
Nagahashi, Masayuki
Akashi-Tanaka, Sadako
Daimon, Takashi
Miyoshi, Yasuo https://orcid.org/0000-0001-8535-4008
-
Funding
Funding for this research was provided by:
Hyog Medical University (No munber)
- License Information
-
More Information
Article History
Received: 4 October 2024
Accepted: 1 February 2025
First Online: 20 February 2025
Declarations
:
: YM received research funding and honoraria from Eisai, Chugai, AstraZeneca, Eli Lilly, Pfizer, MSD, Kyowa-Kirin, Daiichi-Sankyo, and Taiho, and consulting fees from Daiichi-Sankyo. MI received consulting fees from Ono Pharmaceutical, Santen Pharmaceutical and Takeda Pharmaceutical. MN received honoraria from Chugai, AstraZeneca, Eli Lilly, Pfizer, Novartis, Taiho, Daiichi Sankyo, Eisai, Kyowa Kirin, and Denka. SA received payment for lectures from Eisai and the board members of JBCS, JABTS, JOPBS, and JBSGO. TD received consulting fees from Ajinomoto, Astellas Pharma, Chugai Pharmaceutical, Daiichi-Sankyo Company, Eisai, Ferring Pharmaceuticals, Healios, Ono Pharmaceutical, and Terumo Corporation. The other authors declare no conflicts of interest related this study.
: This study was approved by the Ethics Committee of the Hyogo College of Medicine (approval no. 1969). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study written informed consent is not required.
